EP1069903A1 - Nouveaux analogues de nucleosides et leurs utilisations dans le traitement de maladies - Google Patents

Nouveaux analogues de nucleosides et leurs utilisations dans le traitement de maladies

Info

Publication number
EP1069903A1
EP1069903A1 EP99912434A EP99912434A EP1069903A1 EP 1069903 A1 EP1069903 A1 EP 1069903A1 EP 99912434 A EP99912434 A EP 99912434A EP 99912434 A EP99912434 A EP 99912434A EP 1069903 A1 EP1069903 A1 EP 1069903A1
Authority
EP
European Patent Office
Prior art keywords
compound
oriented
fluoro
evaporated
deoxyuridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99912434A
Other languages
German (de)
English (en)
Inventor
Alexander L. Weis
Kirupathevy Pulenthiran
Annette M. Gero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unisearch Ltd
Lipitek International Inc
Original Assignee
Unisearch Ltd
Lipitek International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/038,647 external-priority patent/US5939402A/en
Application filed by Unisearch Ltd, Lipitek International Inc filed Critical Unisearch Ltd
Publication of EP1069903A1 publication Critical patent/EP1069903A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to novel nucleosides and dinucleoside dimers and derivatives of these compounds, including, L-deoxyribofuranosyl nucleoside phosphodiester dimers in which the sugar moiety of at least one of the nucleosides has an L-configuration.
  • These compounds are highly effective in the treatment of various diseases. They may be used to treat parasitic infections such as the one caused by Plasmodium falciparum, the etiologic agent responsible for the most fatal form of malaria. They may also be used to treat bacterial, viral, and fungal infections, and may also be used to treat cancer.
  • Modified nucleoside analogs are an important class of antineoplastic and antiviral drugs.
  • the present application discloses novel compounds for of this type for use in the treatment of P. falciparum infection and other parasitic infections.
  • Plasmodium falciparum is the etiologic agent responsible for the most fatal form of malaria, a disease which afflicts between 200 and 300 million people per year (all forms), including over one million childhood deaths. Additionally, greater than 40% of the world's population lives in areas in which malaria is at epidemic levels. Due to the extraordinary morbidity and mortality associated with malaria and other parasitic infections, related research has intensified during the past decade in a desperate search for effective treatments. Safe and effective vaccines still do not exist. Instead, many victims must depend upon chemotherapy.
  • modified nucleoside analogs may also be used to treat various other parasitic infections, bacterial infections, fungal infections, viral infections, and cancer.
  • chemotherapeutic agents can be classified into two groups: those that act post-translationally, and those that act by interfering with nucleic acid synthesis.
  • Most drugs are in the first group, which means that they exert their therapeutic effect by interfering with a cell's protein synthesis, and hence its metabolism (rather than its nucleic acid synthesis).
  • Examples of drugs in this group include: the antifolate compounds (which inhibit dihyrdofolate reductase), and sulfonamide drugs (which inhibit dihydropteroate synthetase.
  • drugs in this group include: the antifolate compounds (which inhibit dihyrdofolate reductase), and sulfonamide drugs (which inhibit dihydropteroate synthetase.
  • the protozoan responsible for malaria very quickly develops resistance to these drugs. The reason is that, since resistance occurs through adaptive mutations in successive generations of the parasite, a one or two point mutation is often sufficient to confer resistance. Bacterial,
  • the second group of compounds includes the nucleic acid intercalators such as acridines, phenanthrenes and quinolines. These intercalators partially mimic the biochemical activity of nucleic acids, and therefore are incorporated into the protozoan's, or a cell's, nucleic acid (DNA and RNA), though once incorporated, do not allow further nucleic acid synthesis, hence their effectiveness. At the same time, these intercalators interfere with host nucleic acid synthesis as well, and thus give rise to toxic side effects. Because of the potential for toxic side effects, these drugs can quite often be given only in very small doses. Once again, a resistance pattern may develop. For example, a number of protozoans are known to develop "cross-resistance,” which means that the parasites develop resistance to other classes of drugs even though they were exposed to a different class of drug.
  • L-nucleosides may be used as highly selective drugs against parasite infection, or against any other type of cell or organism utilizing the L-nucleosides.
  • the chemical modification of the L-nucleosides consists generally of modifying the nucleosides so that they are still recognized by the invading cell or organism's nucleic acid synthetic machinery, and therefore incorporated into a nucleic acid chain, but yet once this incorporation occurs, no further synthesis will take place.
  • dimers of these nucleoside analogs are well known, dimers in which one or both nucleosides are of the unnatural L-configuration are much less known, and their use in therapy of neoplastic and viral diseases is unknown.
  • nucleoside dimers In the synthesis of DNA-related oligomers, types of nucleoside dimers are synthesized as part of the overall process. These dimers usually include bases from naturally occurring DNA or RNA sequences. There is much known in the art about nucleoside monophosphate dimers. Many of these compounds have been synthesized and are available commercially. However, these dimers are made from nucleosides containing a sugar moiety in D-configuration.
  • Reese, C.B., Tetrahedron 34 (1978) 3143 describes the synthesis of fully-protected dinucleoside monophosphates by means of the phosphotriester approach.
  • the methods are applicable to synthesis of dimers, both by solution phase and solid phase methods. Both phosphitetriester and phosphotriester methods of coupling nucleosides are described.
  • the solid phase method is useful for synthesizing dimers.
  • dimers with L-deoxyribofuranosyl moieties in any position are new, as are dimers with L-ribofuranosyl moieties bonded to the 3'-position of the phosphate internucleotide bond.
  • Modified nucleoside analogues represent an important class of compounds in the available arsenal of antineoplastic and antiviral drugs.
  • antisense oligonucleotide analogues with modified bases and/or phosphodiester backbones have been actively pursued as antiviral and antitumor agents. While no clinically approved drug has yet emerged from this class of compounds, it remains a very active field of research.
  • antipodal L-sugar-based nucleosides also have found application as potent antiviral agents because they can inhibit viral enzymes without affecting mammalian enzymes, resulting in agents that have selective antiviral activity without concomitant mammalian cytotoxicity.
  • nucleosides Most naturally occurring nucleosides have the D-configuration in the sugar moiety. While the chemical properties of L-nucleosides are similar to those of their ⁇ -D-enantiomers, they exhibit very different biological profiles in mammalian cells and do not interfere with the transport of normal D-nucleosides. For example, ⁇ -L-uridine is not phosphorylated at the 5'-position by human prostate phosphotransferase, which readily phosphorylates the enantiomeric ⁇ -D-uridine. Moreover, L-nucleosides are not substrates for normal human cell kinases, but they may be phosphorylated by viral and cancer cell enzymes, allowing their use for the design of selective antiviral and anticancer drugs.
  • Oligonucleotides based on L-nucleosides have been studied previously. Octamers derived from ⁇ - and ⁇ -L-thymidine were found resistant to fungal nucleases and calf spleen phosphodiesterase, which readily degrades the corresponding ⁇ -D-oligonucleotide. Fujimory, et al., S. Fujimory, K. Shudo, Y. Hashimoto, J. Am. Chem. Soc, 112, 7436, have shown that enantiomeric poly- ⁇ -DNA recognizes complementary RNA but not complementary DNA. This principle has been used in the design of nuclease-resistant antisense oligonucleotides for potential therapeutic applications.
  • L-nucleoside-based compounds have potential as drugs against neoplastic, fungal, and viral diseases, as well as against parasitic infections. While L-sugar-derived nucleosides and their oligonucleotides have been widely evaluated for such activities, little is known regarding the biological activities of shorter oligomers such as dimers obtained by L-nucleoside substitution.
  • This invention comprises novel L-nucleoside-derived antitumor, antiviral, antibacterial, antifungal, and antiparasitic agents.
  • Novel L-nucleoside-derived dinucleoside monophosphates based on L- ⁇ -5-fluoro-2'-deoxyuridine showed a remarkably high potency activity profile in in vitro assays, with indications of unique mechanisms of action, including inhibition of telomerase. Therefore, the L-nucleosides can serve as building blocks for new drugs with the special advantage of low toxicity.
  • a further embodiment of the present invention is the administration of a therapeutically effective amount of the compounds of the present invention for the treatment of cancer, viral infections, parasitic infections, fungal infections, and bacterial infections.
  • Figure 1 is a schematic representation of examples of the dinucleotide dimers of the present invention.
  • Figures 2-14 are schematic representations of examples of the synthesis schemes followed in the present invention.
  • Figures 15A and 15B are schematic representations of examples of dinucleoside phosphate dimers containing alternate backbones.
  • Figures 16A-16D are schematic representations of dinucleoside phosphate dimers used in the examples.
  • the term "dimers" as used herein is defined by the structures shown in Figure 1. These compounds are L-nucleoside-derived dinucleoside monophosphates.
  • the B 1 and B 2 units will consist of either a ⁇ -D, a ⁇ -L or an ⁇ -L nucleoside and at least one of B ⁇ or B 2 will be ⁇ -L or ⁇ -L.
  • R and R 2 will be the pyrimidine bases cytosine, thymine, uracil, or 5-fluorouridine (5-FUdR) other 5-halo compounds, or the purine bases, adenosine, guanosine or inosine.
  • the dimers can be bound by various linkages.
  • Permissible linkages include 5'-3', 3'-5', 3'-3', 5'-5', 2'-3', 3'-2', 2' ⁇ 2', 2'-5', 5'-2', or any other stereochemically permissible linkage.
  • the sugar part of the nucleoside may be fully oxygenated, or may be in the deoxy or dideoxy form.
  • Specific antidisease compounds which are useful in the present invention include 3'-O-( ⁇ -L-5-fluoro-2'-deoxyuridinyl)- ⁇ -D-5-fluoro-2'-deoxyuridine,(L-102), 3'-O-( ⁇ -D-5-fluoro-2'-deoxyuridinyl)- ⁇ -L-5-fluoro-2'-deoxyuridine, (L-103), 3'-O-( ⁇ -D-5-fluoro-2'-deoxyuridinyl)- ⁇ -L-2'-deoxyuridine, (L-107), 3'-O-( ⁇ -L-5-fluoro-2'-deoxyuridinyl)- ⁇ -L-5-fluoro-2'-deoxyuridine, (L-108), 3'-O-( ⁇ -L-5-fluoro-2'-deoxyuridinyl)- ⁇ -L-5-fluoro-2'-deoxyuridine, (L-109), 3'-O-( ⁇ -D-5-fluoro-2
  • nucleotide binding agent or "IBA” means the backbone binding which links the nucleosides together.
  • IBA internucleotide binding agent
  • Figure 6 where methoxy phosphotriesters, methylphosphonates, phosphorodithioates, phosphorothioates, silyl ethers, sulphonates and ethylenedioxy ethers are shown.
  • the IBA's can be used to link the sugars 5'->3', 3' ⁇ 5', 3'-3', 5'-5', 2'-3', 3' ⁇ 2', 2'-2', 2'-5', 5' ⁇ 2', or any other stereochemically permissible linkages.
  • the sugars may be fully oxygenated, or may be in the deoxy or dideoxy form as permitted.
  • the IBA of the compounds is either phosphodiester or phosphorothioate.
  • the term "antidisease” as used herein refers to any of the activities of the compounds of the present invention to affect a disease state, including antitumor, antineoplastic, anticancer, antiparasitic and antiviral activity.
  • a compound or composition is said to be "pharmacologically acceptable” if its administration can be tolerated by a recipient mammal.
  • Such an agent is said to be administered in a "therapeutically effective amount” if the amount administered is physiologically significant.
  • An agent is physiologically significant if its presence results in technical change in the physiology of a recipient mammal. For example, in the treatment of cancer or neoplastic disease, a compound which inhibits the tumor growth or decreases the size of the tumor would be therapeutically effective; whereas in the treatment of a viral disease, an agent which slows the progression of the disease or completely treats the disease, would be considered therapeutically effective.
  • the antidisease compounds (active ingredients) of this invention can be formulated and administered to inhibit a variety of disease states (including tumors, neoplasty, cancer, bacterial, fungal, parasitic and viral diseases) by any means that produces contact of the active ingredient with the agent's site of action in the body of a mammal. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic active ingredients or in a combination of therapeutic active ingredients. They can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
  • the dosages given as examples herein are the dosages usually used in treating tumors, neoplasty and cancer. Lower doses may also be used. Dosages for antiparasitic and antiviral applications will, in general, be 10-50% of the dosages for anticancer applications.
  • the dosage administered will be a therapeutically effective amount of active ingredient and will, of course, vary depending upon known factors such as the pharmacodynamic characteristics of the particular active ingredient and its mode and route of administration; age, sex, health and weight of the recipient; nature and extent of symptoms; kind of concurrent treatment, frequency of treatment and the effect desired.
  • a daily dosage (therapeutic effective amount) of active ingredient can be about 5 to 400 milligrams per kilogram of body weight. Ordinarily, 10 to 200, and preferably 10 to 50, milligrams per kilogram per day given in divided doses 2 to 4 times a day or in sustained release form is effective to obtain desired results.
  • Dosage forms (compositions) suitable for internal administration contain from about 1.0 to about 500 milligrams of active ingredient per unit.
  • the active ingredient will ordinarily be present in an amount of about 0.05-95% by weight based on the total weight of the composition.
  • the active ingredient can be administered orally in solid dosage forms such as capsules, tablets and powders, or in liquid dosage forms such as elixirs, syrups, emulsions and suspensions.
  • the active ingredient can also be formulated for administration parenterally by injection, rapid infusion, nasopharyngeal absorption or dermoabsorption.
  • the agent may be administered intramuscularly, intravenously, or as a suppository.
  • Gelatin capsules contain the active ingredient and powdered carriers such as lactose, sucrose, mannitol, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
  • Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
  • water a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
  • Solutions for parenteral administration contain preferably a water soluble salt of the active ingredient, suitable stabilizing agents and, if necessary, buffer substances.
  • Antioxidizing agents such as sodium bisulfate, sodium sulfite or ascorbic acid, either alone or combined, are suitable
  • stabilizing agents are citric acid and its salts and sodium EDTA.
  • parenteral solutions can contain preservatives such as benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, a standard reference text in this field.
  • control release preparations can include appropriate macromolecules, for example polymers, polyesters, polyaminoacids, polyvinyl, pyrolidone, ethylenevinylacetate, methyl cellulose, carboxymethyl cellulose or protamine sulfate.
  • concentration of macromolecules as well as the methods of incorporation can be adjusted in order to control release.
  • the agent can be incorporated into particles of polymeric materials such as polyesters, polyaminoacids, hydrogels, poly (lactic acid) or ethylenevinylacetate copolymers. In addition to being incorporated, these agents can also be used to trap the compound in microcapsules.
  • Useful pharmaceutical dosage forms for administration of the compounds of this invention can be illustrated as follows.
  • Capsules are prepared by filling standard two-piece hard gelatin capsulates each with 100 milligram of powdered active ingredient, 175 milligrams of lactose, 24 milligrams of talc and 6 milligrams magnesium stearate.
  • Soft Gelatin Capsules A mixture of active ingredient in soybean oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules are then washed and dried.
  • Tablets are prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient. 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of comstarch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or to delay absorption.
  • a parenteral composition suitable for administration by injection is prepared by stirring 1.5% by weight of active ingredients in 10% by volume
  • aqueous suspension is prepared for oral administration so that each 5 millimeters contain 100 milligrams of finely divided active ingredient, 200 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution U.S. P. and 0.025 millimeters of vanillin.
  • the nucleosides and dimers may incorporate any stereochemcially permissible linkage and may include various oxygenated, deoxy, and dideoxy forms of the sugar rings.
  • the synthetic nucleosides and dimers described in the examples can include any of the substitutions discussed earlier.
  • the backbone and base modifying groups can be added. Various substitutions will enhance the affinity, the chemical stability and the cellular uptake properties of the specific dimers treatments.
  • CISiMe 3 (2.3 ml, 18.05 mmol) was added dropwise over 30 minutes to a stirring suspension of compound 17 (0.82 g, 3.61 mmol) in pyridine (50 ml) chilled in an ice bath.
  • BzCI (2.1 ml, 18.05 mmol) was then added dropwise and the reaction mixture was cooled at room temperature for two hours. The reaction mixture was again cooled in an ice bath and cold water (10 ml) was added dropwise. Fifteen minutes later, concentrated NH 4 OH (10 ml) was added to produce a solution of ammonia of a concentration of about 2M. Thirty minutes after the addition of the ammonia solution, a solvent was evaporated, dissolved in water and washed with ether. Evaporation of this aqueous solution provided the crude product (18) which was used in the next step without further purification.
  • the dimers were prepared from the monomeric materials by the general scheme shown in Scheme 2.
  • A. ⁇ -L. ⁇ -D 5 FUdR Dimer ⁇ '-O-dimethoxytrityl- ⁇ -L-S-fluoro ⁇ '-deoxyuridine (20a) ⁇ -L-5-fluoro-2'-deoxyuridine (8) (500 mg, 2.0 mmol) was dissolved in 10 ml of dry, distilled pyridine. To this solution was added 4,4'-dimethoxytrityl chloride (813 mg, 2.4 mmol) and 4-dimethylaminopyridine (DMAP) (50 mg, 0.4 mmol). The mixture was stirred under an argon atmosphere for 16 hours. After this time, the pyridine was stripped off in vacuo.
  • DMAP 4-dimethylaminopyridine
  • the 5'-O-dimethoxytrityl- ⁇ -L-5-fluoro-2'-deoxyuridine (20a, 548 mg, 1 mmol) was dissolved in anhydrous dichloromethane (20 ml).
  • N,N-diisopropylethylamine 700 ⁇ l, 4 mmol was added through a septum, followed by chloro-N,N-diisopropylmethoxyphosphine (290 ⁇ l, 1.5 mmol), under an argon atmosphere.
  • the reaction was stirred for 30 minutes.
  • the solvent was evaporated and the residue was partitioned between an 80% EtOAc/triethylamine mixture and brine.
  • the organic layer was washed with saturated NaHCO 3 solution and brine.
  • the dimer, 25a (504 mg), was dissolved in 8 ml of THF and 2 ml of pyridine containing 0.2 ml of water. Iodine crystals (26 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 2.1 hours. Excess iodine was discharged by the addition of a few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was dissolved in EtOAc washed with saturated NaHCO 3 solution and brine. The organic layer was dried over Na 2 SO 4 , filtered and evaporated in vacuo.
  • the O-protected dimer, 26a (280 mg) was treated with 20 ml of saturated methanolic ammonia at room temperature until the reaction was completed at room temperature. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH 4 CO 3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40° C in high vacuo to dryness to give the pure product (162 mg).
  • the dimer, 25b (526 mg), was dissolved in 8 ml of THF and 2 ml of pyridine containing 0.2 ml of water. Iodine crystals (26 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was discharged by the addition of a few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was dissolved in EtOAc washed with saturated NaHCO 3 solution and brine. The organic layer was dried over Na 2 SO 4 , filtered and evaporated in vacuo. The residue (578 mg) was dissolved in 10 ml of 80% acetic acid/water solution and was stirred for three hours.
  • the dimer, 25c (2.81 g, 3.2 mmol), was dissolved in a mixture of THF:pyridine:water (25:6:0.6). Iodine crystals (150 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was discharged by the addition of a few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was dissolved in EtOAc washed with saturated NaHCO 3 solution and brine. The organic layer was dried over Na 2 SO 4 , filtered and evaporated in vacuo.
  • the O-protected dimer, 26c (465 mg, 0.78 mmol) was treated with 50 ml of saturated methanolic ammonia at room temperature until the reaction was completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH 4 CO 3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40°C in high vacuo to dryness to give the pure product (370 mg, 87.7% yield).
  • the 5'-O-dimethoxytrityl- ⁇ -L-5-fluoro-2'-deoxyuridine (20d, 840 mg, 1.53 mmol) was dissolved in anhydrous dichloromethane (50 ml). N,N-diisopropylethylamine (1.1 ml, 6.13 mmol) was added through a septum, followed by chloro-N,N-diisopropylmethoxyphosphine (0.42 ml, 2.3 mmol), under an argon atmosphere. The reaction was stirred for 30 minutes. The solvent was evaporated and the residue was partitioned between an 80% EtOAc/triethylamine mixture and brine.
  • the dimer, 25d (960 mg, 1.07 mmol), was dissolved in a mixture containing
  • the O-protected dimer, 26d (300 mg, 0.49 mmol) was treated with 50 ml of saturated methanolic ammonia at room temperature until the reaction was completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH 4 CO 3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40°C in high vacuo to dryness to give the pure product (240 mg, 85% yield).
  • the dimer in reduced form 25 (700 mg, 0.78 mmol), was dissolved in a mixture containing THF:pyridine:water (25:6:0.6). Iodine crystals (100 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 2.5 hours. Excess iodine was discharged by the addition of a few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was dissolved in EtOAc washed with saturated NaHCO 3 solution and brine. The organic layer was dried over Na 2 SO 4 , filtered and evaporated in vacuo. The residue was dissolved in 25 ml of 80% acetic acid/water solution and was stirred until the reaction was completed.
  • the O-protected dimer, 26e (340 mg, 0.57 mmol) was treated with 100 ml of saturated methanolic ammonia at room temperature until the reaction was completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH 4 CO 3 buffer from 0.02-0.2
  • the dimer, 25f (970 mg), was dissolved in 16 ml of THF and 4 ml of pyridine containing 0.4 ml of water. Iodine crystals (50 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was discharged by the addition of few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was EtOAc washed with saturated NaHCO 3 solution and brine. The organic layer was dried over Na 2 SO 4 , filtered and evaporated in vacuo. The residue was dissolved in 20 ml of 80% acetic acid/water solution and was stirred until the reaction was completed.
  • the O-protected dimer, 26f (200 mg) was treated with 20 ml of concentrated ammonia solution until the reaction is completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH 4 CO 3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40° C in high vacuo to dryness to give the pure product (79 mg).
  • the dimer 25g (611 mg), was dissolved in 8 ml of THF and 2 ml of pyridine containing 0.2 ml of water. Iodine crystals (30 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was discharged by the addition of few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was EtOAc washed with saturated NaHCO 3 solution and brine. The organic layer was dried over Na 2 SO 4 , filtered and evaporated in vacuo. The residue was dissolved in 20 ml of 80% acetic acid/water solution and was stirred until the reaction was completed.
  • the o-protected dimer, 26g (200 mg) was treated with 20 ml of concentrated ammonia solution until the reaction is completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH 4 CO 3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40°C in high vacuo to dryness to give the pure product (134 mg).
  • the O-protected dimer, 26h (400 mg) was treated with 100 ml of methnolic ammonia solution until the reaction is completed.
  • the solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH 4 CO 3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40° C in high vacuo to dryness to give the pure product (175 mg).
  • N -benzoyl-2'-deoxy- ⁇ -L-cytidine (0.8 g, 2.42) was dissolved in 50 ml of dry, distilled pyridine. To this solution was added 4,4'-dimethoxytrityl chloride (3.0 g, 8.85 mmol) and 4-dimethylamino pyridine (DMAP) (60 mg, 0.48 mmol). The mixture was stirred under an argon atmosphere for 16 hours. After this time, the pyridine was stripped off in vacuo. The residue was dissolved in EtOAc (100 ml). The organic layer was washed with water, saturated NaHCO 3 , and brine.
  • DMAP 4-dimethylamino pyridine
  • the dimer, 25i (0.73 g), was dissolved in 20 ml of THF and 4 ml of pyridine containing 0.4 ml of water. Iodine crystals (100 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was discharged by the addition of few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was EtOAc washed with saturated NaHCO 3 solution and brine. The organic layer was dried over Na 2 SO 4 , filtered and evaporated in vacuo. The residue was dissolved in 25 ml
  • the O-protected dimer, 26i (108 mg) was treated with 100 ml of methnolic ammonia solution until the reaction is completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH 4 CO 3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40°C in high vacuo to dryness to give the pure product (56 mg).
  • the dimer, 25j (0.49 g), was dissolved in 8 ml of THF and 2 ml of pyridine containing 0.2 ml of water. Iodine crystals (30 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was
  • the O-protected dimer, 26j (188 mg) was treated with 100 ml of concentrated ammonia solution until the reaction is completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH 4 CO 3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40°C in high vacuo to dryness to give the pure product (105 mg).
  • the dimer 25k (0.42 g), was dissolved in 10 ml of THF and 2 ml of pyridine containing 0.2 ml of water. Iodine crystals (45 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was discharged by the addition of few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was EtOAc washed with saturated NaHCO 3 solution and brine. The organic layer was dried over Na 2 SO 4 , filtered and evaporated in vacuo. The residue was dissolved in 25 ml of 80% acetic acid/water solution and was stirred until the reaction was completed.
  • the O-protected dimer, 26k (125 mg) was treated with 100 ml of concentrated ammonia solution until the reaction is completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH 4 CO 3 buffer from 0.02-0.2 M). Pure fractions were evaporated at 40°C in high vacuo to dryness to give the pure product (40 mg).
  • telomerase is a DNA-processive enzyme that is not expressed in normal somatic cells but generally only in germ-line cells and fetal cells. In many types of cancer cells, enzyme activity is reactivated, and others, telomerase inhibitors can therefore serve as a valuable new class of antineoplastic agents. The results are shown in Table 2.
  • the preliminary results of the telomerase inhibition are also interesting.
  • the ⁇ -L, ⁇ -D dimer inhibited the enzyme by 84% compared to control.
  • dimers containing an L-sugar have extremely interesting biological profiles and represent a novel class of potent antineoplastic agents.
  • the activity profile of the L-dimers is different from that of the parent monomeric drug ⁇ -D-5FUdR.
  • Thymidylate synthase is one suspected site of action of the compounds.
  • the activity of selected compounds of the present invention measured on thymidylate synthase activity measured in vitro, is a reliable indicium of the behavior of these compounds in in vivo systems.
  • Mouse leukemia L1210 cells are harvested from the cell culture flasks and the cell concentration is determined. The cells are then resuspended in the desired amount of the medium to give a stock concentration 5x10 7 cells/mL. Series of the
  • 38 dilution of the stock solution of the compounds to be tested are prepared (concentrations are ranged from 10 8 M to 10 "3 M).
  • the solution of the compound to be tested in the desired concentration is pipetted into a microcentrifuge tube and incubated at 37 °C using a shaking water bath.
  • the reaction is started by addition of [5- 3 H]-2 '-deoxycytidine (10 ⁇ L, concentration of the stock solution - 10 "5 M) after a 30 or 60 min. preincubation with 80 ⁇ L of the cell suspension and allowed to proceed for 30 min. in a shaking water bath at 37°C.
  • the reaction is terminated by adding 100 ⁇ L of the 10% charcoal in 4% HC1 O 4 .
  • the tubes are vigorously stirred by vortexing and then centrifuged for 10 min. in a Beckman Microfuge.
  • the radioactivity of a 100 ⁇ L of supernatant fraction from each tube is counted in a Packard Tri-Carb (model 2450 or 3255) liquid scintillation spectrometer using a toluene based scintillation mixture.
  • the release of tritium is expressed as a percentage of the total amount of radioactivity added.
  • IC 50 values determined from dose response curves represent the concentration of inhibitors required for 50% inhibition of the release of tritium. Table 3 below shows the results of the analysis of tritium release and determination of the IC 50 .
  • B6D2F1 mice received i.p. inocula of P388 murine leukemia cells prepared by removing ascites fluid containing P388 cells from tumored B6D2F1 mice, centrifuging the cells, and then resuspending the leukemia cells in saline.
  • Mice received 1 x 10 6 P388 cells i.p. on day 0.
  • tumored mice were treated with the dimers or vehicle control.
  • the route of drug administration was i.p. and the schedule selected was daily x 5.
  • the maximum tolerated doses (MTD) was 200 mg/kg for each dimer and was determined in initial dose experiments in non-tumored mice. In the actual experiments, L-103 was given at 100 mg/kg and 50 mg/kg.
  • B6D2F1 mice received i.p. inocula of B16 murine melanoma brei prepared from B16 tumors growing s.c. in mice (day 0). On day 1 , tumored mice were treated with the dimers or vehicle control. The route of drug administration was i.p. and the schedule selected was daily x 5. The maximum tolerated doses (MTD) was 200 mg/kg for each dimer and was determined in initial dose experiments in non-tumored mice. In the actual experiments, L-103 was given at 100 mg/kg and 50 mg/kg.
  • T/C mean survival of control mice
  • mice that survive for 30 days are considered long term
  • T/C 125.
  • T/C 125-150, weak activity
  • T/C 150-200, modest activity
  • T/C 200-300, high activity
  • T/C > 300 with long term survivors; excellent, curative activity.
  • L-103 demonstrated modest activity against B16 melanoma implanted in mice (Table 6). L-103 (i.p.; daily x 5) gave T/C values of 139 and 134 respectively.
  • L-103 demonstrated modest activity against both the P388 and B16 experimental murine tumors at the two doses tested. L-103 was approximately as active as the positive control drug FUdR in the B16 test, and was somewhat less active than FUdR in the P388 test.
  • P. falciparum, FCQ27 was maintained in culture using the techniques described by Trager & Jensen (W. Traqer and J.B. Jensen, Science, 193 673-675 (1976)). Cultures containing 2% hematocrit suspensions of parasitized human type O+ erythrocytes in RPMI 1640 medium, supplemented with 25 mM HEPES-KOH, pH 7.2, 25 mM NaHCO3 and 10% human type O+ serum (v/v) are maintained in modular incubator chambers at 37° C in a gas mixture of 5% 02, 5% CO2 and 90% N2. The isolate of P. falciparum used in these experiments was FCQ27, routinely maintained in synchronized or asynchronous in vitro cultures at low hematocrit.
  • nucleoside analogues against P. falciparum in culture were tested in microtitre plates over the range of drug concentrations for 24 hours.
  • the procedures for monitoring parasite viability is well established (A.M. Gero, H.V. Scott, W.J. O'Sullivan and R.I. Christopherson, Mol. Biochem. Parasitol. 34, 87-89 (1989)) and is based on radiolabelled hypoxanthine or isoleucine incorporation.
  • the incorporation of [G-3H]hypoxanthine into the nucleic acids of P. falciparum was used to assess the viability of the parasite in vitro.
  • Microculture plates were prepared with each well containing 225 ⁇ l of a 2% hematocrit culture of asynchronous parasited erythrocytes (1% parasitized cells). Each plate, containing varying concentrations of the drug to be studied (up to 200 ⁇ M final concentration for initial screen), was incubated for 24 h at 37° C in a gas mixture of 5% O2, 5% CO2 and 90% N2, at which point [G-3H] hypoxanthine was added to each well and the incubation continued under identical conditions for a further 18-20 h. The control infected cells (i.e. without drug), routinely reached a parasitemia of 6-8% before harvesting.
  • the metabolism of the L-nucleoside conjugates was studied by HPLC analysis. The primary aim was to determine their ability to be catabolized by parasite purine salvage enzymes. Some effect on the purine metabolic pools was also observed.
  • trophozoite infected cells For each HPLC determination 200 ⁇ L of packed cells of 80-90% trophozoite infected cells were used. These were isolated from in vitro cultures by synchronization of the parasites in in vitro cultures using sterile D-sorbitol (L. Lambros and J.P. Vanderberg, Parasitol. 65, 418-420 (1979)) followed by separation of the trophozoites from non infected erythrocytes by Percoll gradients as described previously (A.M. Gero, H.V. Scott, W.J. O'Sullivan and R.I. Christopherson, Mol. Biochem. Parasitol. 34, 87-89 (1989)). Trophozoites were incubated at 37 °C for 2 hours with each compound to be tested.
  • Drug incubation was terminated by centrifugation through silicon oil using the method of Upston and Gero (J.M. Upston and A.M. Gero, Biochem. Biophys. Acta. 1236, 249-258 (1995)). This procedure separated intact trophozoites from extracellular non-transported drug solution.
  • nucleosides with potential chemotherapeutic activity were assessed by the analysis of cytoplasmic samples by reverse phase ion-pair high performance liquid chromatography (R.S. Toguzov, YN. Tikhonov, A.M. Pimenov, V. Prokudin, Journal of Chromatography, I. Biomedical Appl. 434, 447-453 (1988)). Nucleotides, nucleosides and bases were separated by this HPLC method.
  • Nucleosides have attracted researchers as potential therapeutic agents. Naturally occurring nucleosides are usually in the ⁇ -D configuration. Therefore most of nucleoside analogues designed for the treatment of cancer, viral and parasitic diseases have been synthesized in this stereochemical configuration. Recent discoveries in our laboratories at the University of Georgia, the University of Iowa and at Yale University, as well as at universities in France and Italy, have confirmed that most L-nucleosides exhibit low toxicity because normal cells do not utilize them for building RNA or DNA and don't metabolize them.
  • FUdR AS inhibitor of thymidylate synthase, and an L-nucleoside or its derivatives.
  • FUdR has a potential as an antimalarial agent (S.A. Queen, D.L. Vander Jagt & P. Reyer, Antimicrobial Agents & Chemotherapy. 34, 1393-1398 (1990).
  • FUdR's toxicity limits its use.
  • combining FUdR with an L-nucleoside unit would result in an entity that could selectively transport an active component to infected cells while having no effect on normal cells.
  • the conjugates tested were: a) dinucleoside phosphates, b) dinucleoside phosphorothioates, c) SATE derivatives of L-nucleosides, and d) L-nucleoside conjugates of nitrobenzylthionosine (NBMPR).
  • NBMPR nitrobenzylthionosine
  • the biological screen involved evaluation of the compounds against the protozoan P. falciparum in in vitro culture.
  • the range of drug concentrations was used independently by two assays.
  • microscopic counting of Giemsa stained thin slides was used as a control.
  • the results of the biological assays are presented in Table 1. Examples of experimental curves are attached as Appendix 2. The biological tests
  • A6 were done at several concentrations. The highest concentration was 200 ⁇ M, the compounds were considered active at concentrations less than 40 ⁇ M.
  • the dimer containing only the "non-natural” isomeric form of nucleoside (L-109) did not exhibit any activity.
  • ⁇ -D-isomer of FUdR is the active component of the dimer molecules.
  • the position of the active component in the dimer is important.
  • the ⁇ -D-FUdR needs to be connected to the 3'-OH end of the L-nucleoside through a phosphodiester linkage to its 5'-OH.
  • Compounds which are linked through 3'-OH of FUdR are much less active (see Table 7). This indicates that the substitution pattern of ⁇ -D-FUdR is critical for the activity of the dimers and most probably the mechanism involves thymidylate synthase inhibition. It is well known that TS inhibitors of FUdR have very rigid structural requirements and do not allow for any substitution at the 3' end.
  • L-138 ( ⁇ -L-da, ⁇ -D-FUdR) 5 L-138 ( ⁇ -L-dA, ⁇ -D-FUdR) 100
  • the different activity of the dimers is dependent on the structure of the second nucleoside.
  • Dimer may act as a new chemical entity without hydrolysis of the phosphate or pro-phosphate bond between the two monomeric units;
  • nucleoside analogs are dependent in kinase-mediated activation to generate the bioactive nucleotide and ultimately, the nucleoside triphosphate (C. Periqaud, G.
  • nucleoside monophosphates themselves, due to their polar nature, are not able to cross the cell membrane efficiently (K.C. Leibman, C.J. Heidelberg, J. Biol. Chem. 216, 823 (1995)). Hence the idea of temporarily masking or reducing the phosphate negative charges with neutral substituents, thereby forming more lipophilic derivatives which would be expected to revert back to the nucleoside mono-phosphate once inside the cell.
  • L-nucleoside dimers L-101 , L-103, L-103A, L-107, L-110, L-111 , L-112, L-114, L-117, L-120, L-122,
  • L-124, L-125, L-133 & L-138) from Lipitek's library were submitted for in vitro screen to the U.S. Army Antimalarial Test Program (for the structures of the compounds, see Figure 7).
  • the compounds have been tested for their activity against two P. falciparum strains: D6 (chloroquin non-resistant) and W2 (chloroquin resistant). Seven (7) of the tested compounds exhibited activities below 40 ⁇ M against both strains of P. falciparum.
  • the most active dimers were L-101 , L-110, L-112, L-117, L-133 & L-138.
  • Column 2 shows the retention times of the original compound remaining after incubation with whole parasite infected cell.
  • Column 3 shows the metabolic products i.e. new peaks due to conversion of the original compound or alteration in the natural purine or pyrimidine profile of the infected cell.
  • nucleosides monophosphate dimers containing ⁇ -D-FUdR unit in combination with any L-nucleosides (L-101 , L-103, L-111 , L-117, L-133, and L-138) as well as tested L-nucleoside monomer analogs (GC1 1007, GC1 1027 & GC1 1069) entered the infected cells. All these compounds were toxic against P. falciparum. The L-109, combination of two L-dimers,
  • Dimethoxytrityl- ⁇ -L-2'-deoxyuridine (1.5 g, 2.83 mmol) was dissolved in anhydrous dichloromethane (50 ml). N, N-diisopropylethylamine (2.0 ml, 11.3 mmol) was added uner argon followed by 2'-cyanoethyl-N,N-diisopropylchlorophosphoramidite (0.82 ml,
  • the dimer (2'-Acetoxy-N 6 -benzoyl-3'-deoxy- ⁇ -D-adenosinyl)- ⁇ -L-2'-deoxyuridinyl cyanoethyl phosphate ester (0.75 g) was treated with ammoniun hydroxide solution (100 ml) over night. The solvent was evaporated and the residue was purified on DEAE Cellulose ion exchange column using gradient of NH 4 HCO 3 buffer (0.05-0.2M). The pure fractions were collected and lyophillized to give pure 3'-O-(3'-deoxy- ⁇ -D-adenosinyl)- ⁇ -L-2'-deoxyuridine (L-150)(0.486 g) as
  • N 6 -benzoyl-5'-O-(di-p-methoxy trityl)-2'-deoxy- ⁇ -L-adenosine (1.64 g, 2.5 mmol) was dissolved in anhydrous dichloromethane (50 ml).
  • N 6 -Benzoyl-5'-O-(dimethoxytrityl)- ⁇ -L-2'-deoxyadenosine-3'-N,N-diisoprop ylcyanoethyl phosphoramidite (2.5 mmol) in anhydrous acetonitrile (60 ml)
  • N 6 -Benzoyl-2'-O-acetoxy- ⁇ -D-3'-deoxyadenosine (0.94 g, 2.36 mmol) in acetonitrile (40 ml) was added and stirred for 10 minutes under argon. 5
  • sublimed 1 H-tetrazole 0.5 g, 7.2 mmol
  • the dimer N 6 -Benzoyl-5'-O-(dimethoxytrityl)-3'-[O-(2'-O-acetyl)-N 6 -benzoyl- ⁇ -D-3-de oxy adenosinyl]-2'-deoxy- ⁇ -L-adenosine cyanoethyl phosphite was 5 dissolved in THF (24 ml), pyridine (6 ml) and water (0.6 ml). Iodine crystals (0.63 g) were added portion wise until the iodine color persists. The reaction mixture was stirred for another 15 minutes and the excess iodine was removed by the addition of saturated sodium thiosulfate. The solvent was evaporated and the residue was dissolved in EtOAc and
  • the dimer (2'-Acetoxy-N 6 -benzoyl-3'-deoxy- ⁇ -D-adenosinyl)-N 6 -benzoyl- ⁇ -L-2'-deoxy adenosinyl cyanoethyl phosphate ester (0.97 g) was treated with ammonium hydroxide solution (100 ml) over night. The solvent was evaporated and the residue was purified on DEAE Cellulose ion exchange column using gradient of NH 4 HCO 3 buffer (0.05 - 0.2 M).
  • the dimer 5'-O-Dimethoxytrityl-3'-[O-(2'-O-acetyl)-N 6 -benzoyl- ⁇ -D-3'-deoxyadenosin yl]-2'-deoxy- ⁇ -L-uridine cyanoethyl phosphite ester was dissolved in THF
  • N 4 -Benzoyl-5'-O-(di-p-methoxy trityl)-2'-deoxy- ⁇ -L-cytidine (1.7 g, 2.68 mmol) was dissolved in anhydrous dichloromethane (50 ml), N, N-diisopropylethylamine (1.9 ml, 10.72 mmol) was added under argon followed by 2'-cyanoethyl-N, N-diisopropylchlorophosphoramidite (0.85 ml, 3.5 mmol). The reaction was stirred for 30 minutes and the solvent was evaporated.
  • the dimer N 4 -Benzoyl-5'-O-dimethoxytrityl-3'-[O-(2'-O-acetyl)-N 6 -benzoyl- ⁇ -D-3'- ⁇ deo xyadenosinyl-2'-deoxy- ⁇ -L-cytidine cyanoethyl phosphite ester was dissolved in THF (24 ml), pyridine (6 ml) and water (0.6 ml). Iodine crystals (0.55 g) were added portion wise until the iodine color persists. The reaction mixture was stirred for another 15 minutes and the excess iodine was removed by the addition of saturated sodium thiosulfate.
  • N-diisopropylethylamine (2.0 ml, 11.6 mmol) was added under argon followed by 2'-cyanoethyl-N, N-diisopropylchlorophosphoramidite (0.85 ml, 3.5 mmol). The reaction was stirred for 30 minutes and the solvent was evaporated. The residue was dissolved in 80% EtOAc/Et 3 N (75 ml) and washed with water, NaHCO 3 and brine.
  • the dimer N 4 -Benzoyl-5'-O-(dimethoxytrityl)-3'-[O-(2'-acetyl)-N 6 -Benzoyl- ⁇ -D-3'-deox y adenosinyl]-2'-deoxy- ⁇ -L-cytidine cyanoethyl phosphite ester was dissolved in THF (24 ml), pyridine (6 ml) and water (0.6 ml). Iodine crystals (0.5 g) were added portion wise until the iodine color persists. The reaction mixture was stirred for another 15 minutes and the excess iodine was removed by the addition of saturated sodium thiosulfate.
  • the dimer (2'-Acetoxy-N 6 -Benzoyl-3'-deoxy- ⁇ -D-adenosinyl)-N 4 -Benzoyl- ⁇ -L-2-deoxy citydinyl cyanoethyl phosphate ester (1.8 g) was treated with ammonium hydroxide solution (100 ml) over night, The solvent was evaporated and the residue was purified on DEAE Cellulose ion exchange column using gradient of NH 4 HCO 3 buffer (0.05 - 0.2M). The pure fractions were collected and lyophillized to give pure
  • N 6 -Benzoyl-3'-O-acetoxy- ⁇ -D-2'-deoxyadenosine (0.94 g, 2.36 mmol) in acetonitrile (40 ml) was added and stirred for 10 minutes under argon.
  • sublimed 1 H-tetrazole 0.5 g, 7.2 mmol
  • the dimer N 6 -Benzoyl-5'-0-dimethoxytrityl-3'-[O-(2'-)-acetyl)-N 6 -benzoyl- ⁇ -D-3'-deoxy adenosinyl]-2'-deoxy- ⁇ -L-adenosine cyanoethyl phosphite ester was dissolved in THF (24 ml), pyridine (6 ml) and water (0.6 ml). Iodine crystals (0.63 g) were added portion wise until the iodine color persists. The reaction mixture was stirred for another 15 minutes and the excess iodine was removed by the addition of saturated sodium thiosulfate.
  • N 6 -Benzoyl-5'-O-(di-p-methoxy trityl )-2'-deoxy- ⁇ -L-adenosine (3.42 g, 74.5%) as pale yellow foam.
  • N 6 -Benzoyl-5'-O-(di-p-methoxy trityl)-2'-deoxy- ⁇ -L-adenosine(1.71 g, 2.61 mmol) was dissolved in anhydrous dichloromethane (50 ml).
  • N, N-diisopropylethylamine (1.8 ml, 10.34 mmol) was added under argon followed by 2'-cyanoethyl-N,N-diisopropylchlorophosphoramidite (1.0 ml, 4.47 mmol). o The reaction was stirred for 30 minutes, and the solvent was evaporated.
  • N 6 -Benzoyl-5'-O-dimethoxytrityl-3'-[O-(3'-O'acetyl)-N 6 -benzoyl- ⁇ -D-2'-deox y adenosinyl]-2'-deoxy- ⁇ -L-adenosine cyanoethyl phosphite ester was dissolved in THF (24 ml), pyridine (6 ml) and water (0.6 ml). Iodine crystals (0.5 g) were added portion wise until the iodine color persists. The reaction mixture was stirred for another 15 minutes, and the excess iodine was removed by the addition of saturated sodium thiosulfate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux nucléosides, de nouveaux dimères de nucléosides dont l'un au moins des nucléosides comporte un sucre L, ainsi que des compositions pharmaceutiques les contenant.
EP99912434A 1998-03-11 1999-03-11 Nouveaux analogues de nucleosides et leurs utilisations dans le traitement de maladies Withdrawn EP1069903A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US38647 1998-03-11
US09/038,647 US5939402A (en) 1995-09-21 1998-03-11 Nucleoside analogs and uses against parasitic infection
US220307 1998-12-23
US09/220,307 US6207649B1 (en) 1995-09-21 1998-12-23 Nucleoside analogs and uses in treating disease
US219947 1998-12-23
US09/219,947 US6242428B1 (en) 1995-09-21 1998-12-23 Nucleoside analogs and uses in treating Plasmodium falciparum infection
PCT/US1999/005360 WO1999045935A1 (fr) 1998-03-11 1999-03-11 Nouveaux analogues de nucleosides et leurs utilisations dans le traitement de maladies

Publications (1)

Publication Number Publication Date
EP1069903A1 true EP1069903A1 (fr) 2001-01-24

Family

ID=27365434

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99912434A Withdrawn EP1069903A1 (fr) 1998-03-11 1999-03-11 Nouveaux analogues de nucleosides et leurs utilisations dans le traitement de maladies

Country Status (5)

Country Link
EP (1) EP1069903A1 (fr)
JP (1) JP2002506036A (fr)
AU (1) AU3080899A (fr)
CA (1) CA2322494A1 (fr)
WO (1) WO1999045935A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007216721B2 (en) * 1998-08-10 2011-05-19 Centre National De La Recherche Scientifique Beta-L-2'-Deoxy Nucleosides for the Treatment of Hepatitis B
AU2004201286B2 (en) * 1998-08-10 2007-06-21 Centre National De La Recherche Scientifique (Cnrs) Beta-L-2'-Deoxy Nucleosides for the Treatment of Hepatitis B
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
ES2579903T3 (es) 1998-08-10 2016-08-17 Centre National De La Recherche Scientifique (Cnrs) Beta-L-2'-desoxi-nucleósidos para el tratamiento de la hepatitis B
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
EP1352910A1 (fr) 2002-04-10 2003-10-15 Grünenthal GmbH Nouveaux derives d'analogues de nitrobenzylthioinosine
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
WO2004069185A2 (fr) * 2003-02-03 2004-08-19 Cv Therapeutics Inc. Agonistes partiels et pleins des recepteurs a1 de l'adenosine
GB0400290D0 (en) * 2004-01-08 2004-02-11 Medivir Ab dUTPase inhibitors
MX2016015568A (es) * 2014-05-28 2017-07-04 Idenix Pharmaceuticals Llc Derivados de nucleosidos para el tratamiento del cancer.
WO2015181624A2 (fr) * 2014-05-28 2015-12-03 Idenix Pharmaceuticals, Inc Dérivés de nucléosides pour le traitement du cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
US5672594A (en) * 1994-10-24 1997-09-30 Genencor International, Inc. L-erythrosyl nucleosides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9945935A1 *

Also Published As

Publication number Publication date
AU3080899A (en) 1999-09-27
WO1999045935A1 (fr) 1999-09-16
CA2322494A1 (fr) 1999-09-16
JP2002506036A (ja) 2002-02-26

Similar Documents

Publication Publication Date Title
US5939402A (en) Nucleoside analogs and uses against parasitic infection
US10968248B2 (en) Trinucleotide mRNA cap analogs
EP0980377B1 (fr) Analogues de nucleosides de pyrimidine antiviraux
US5457187A (en) Oligonucleotides containing 5-fluorouracil
CA1333390C (fr) Nucleosides fluores et methode de traitement des infections retrovirales avec ces nucleosides
EP1280813B1 (fr) Analogues de nucleoside pyrimidique a action antivirale
US20040132684A1 (en) Polymeric nucleoside prodrugs
EP1113020B1 (fr) Nucléosides et oligonucléosides contenant des amas de bore
WO2004080466A1 (fr) Analogues de la cytidine et methodes d'utilisation
EP1069903A1 (fr) Nouveaux analogues de nucleosides et leurs utilisations dans le traitement de maladies
US20120149888A1 (en) Synthesis of ara-2'-o-methyl-nucleosides, corresponding phosphoramidites and oligonucleotides incorporating novel modifications for biological application in therapeuctics, diagnostics, g- tetrad forming oligonucleotides and aptamers
US20180251485A1 (en) Pyrazolotriazolyl nucleoside analogues and oligonucleotides comprising them
Urata et al. Design and racemic synthesis of conformationally restricted carbocyclic pyrimidine nucleoside analogs based on the structure of the L-nucleoside residue in heterochiral DNA
MXPA99009965A (en) Anti-viral pyrimidine nucleoside analogues

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001010

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GERO, ANNETTE, M.

Inventor name: PULENTHIRAN, KIRUPATHEVY

Inventor name: WEIS, ALEXANDER, L.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031001